November 4, 2012

Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis

In this randomized, placebo controlled trial, patients on hemodialysis with moderate-to-severe secondary hyperparathyroidism were randomized to receive either cinacalcet or placebo.   No difference was seen in the primary composite end point (time until death, myocardial infarction, hospitalization for unstable angina, heart failure, or a peripheral vascular event) between cinacalcet (48.2%) versus placebo (49.2%) HR 0.93; 95% CI, 0.85 to 1.02; P=0.11. Hypocalcemia and gastrointestinal adverse events were more common in patients on active treatment.

See the accompanying editorial.

Related Articles:

Bone Mineral Metabolism, Vascular Disease/Calcification

Comments are closed.